Cadrenal Therapeutics CEO Quang Pham Sells Shares
On June 16, 2026, CEO Quang Pham sold 3,613 shares of Cadrenal Therapeutics.
Key Points
- Cadrenal Therapeutics CEO Quang Pham sold 3,613 shares on June 16, 2026, for $11,489.34.
- Shares of NasdaqCM:CVKD traded at $3.50 with a market cap of $9.5 million.
- Cadrenal Therapeutics develops therapies for immune and thrombotic conditions.
Important disclosure: EarningsIQ is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 16, 2026, Quang Pham, the Chairman, CEO, and Interim CFO of Cadrenal Therapeutics, Inc. (NasdaqCM:CVKD), sold 3,613 shares of the company. The shares were sold at an average price of $3.18 each, totaling $11,489.34. This transaction was made under a pre-arranged trading plan.
Cadrenal Therapeutics, Inc. Stock Up 12.9%
Shares of Cadrenal Therapeutics, trading under the ticker CVKD on the Nasdaq Capital Market, are currently priced at $3.50. The company has a market capitalization of approximately $9.5 million. Its forward P/E ratio is not meaningful as the company is not currently profitable, with an EPS of -$5.59. The stock has a beta of 1.613, indicating higher volatility compared to the market. Over the past year, the stock's price ranged from a low of $3.02 to a high of $14.64. The 50-day moving average is $5.02, while the 200-day moving average stands at $8.50. Cadrenal maintains a current ratio of 2.68 and a quick ratio of 2.17, reflecting its ability to meet short-term obligations.
$CVKD stock price
Daily closing prices, year to date. Not investment advice.
About Cadrenal Therapeutics
Cadrenal Therapeutics, Inc. is a biotechnology company based in Ponte Vedra, Florida. It focuses on developing innovative therapies for serious immune and thrombotic conditions. Among its key projects is Tecarfarin, an oral vitamin K antagonist in Phase 3 trials aimed at preventing heart attacks, strokes, and deaths due to blood clots in patients with chronic anticoagulation needs. The company is also working on CAD-1005, a 12-LOX inhibitor for treating heparin-induced thrombocytopenia, and Frunexian, a factor XIa inhibitor for hospital use. Cadrenal collaborates with Abbott Global Enterprises to evaluate Tecarfarin's efficacy and safety in patients with left-ventricular assist devices.
Bottom Line
Quang Pham's sale of shares in Cadrenal Therapeutics is part of a planned trading strategy, reflecting personal financial management rather than a direct comment on the company's outlook. Investors often track insider transactions for insights into management's view of the company's future. However, it's important to note that these transactions are reported after they occur, providing a historical perspective rather than a real-time signal.
Get Cadrenal Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $CVKD, sent to your inbox. Free, and you can unsubscribe anytime.
Related Filing Alerts
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.
S